AIRDOC-B (02251) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 83.713 million and gross profit of RMB 64.103 million, representing a year-on-year increase of 13.53%. The company recorded a profit of RMB 443,000 for the period, compared to a loss of RMB 81.488 million in the same period last year, achieving a turnaround from loss to profit.

According to the announcement, during the reporting period: (i) The group's active service points for retinal detection AI products increased from 5,950 to 7,180, representing a year-on-year growth of 20.7%. The number of unique visitors (UV) to secondary hospitals and primary healthcare facilities in AIRDOC's medical segment grew by 7.2% year-on-year. Through SaMD and health risk assessment solutions, the group conducted a total of 3.3 million case detections during the reporting period, up 11.4% year-on-year. (ii) The usage of the group's myopia prevention and control AI products reached 2.812 million times, up 68.1% year-on-year. Since 2024, the company has been building a distribution service system and star-rated store service system based on PBM-LED myopia phototherapy devices. By the first half of 2025, this product has covered 1,867 optometry stores across 20 provincial administrative regions nationwide. (iii) The training sessions for the group's visual training AI products reached 1.026 million, up 11.6% year-on-year.

During the reporting period, the company further expanded its testing business boundaries and successfully developed and launched a new generation of physiological stress resistance testing product - the "AIRDOC Stress Resistance Testing Device" - based on wireless sensing technology (non-contact detection) and multimodal AI algorithm technology. This product has completed product finalization and market testing.